Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04374019
Other study ID # MCC-20-COVID-01-PMC
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date May 1, 2020
Est. completion date January 12, 2022

Study information

Verified date January 2022
Source University of Kentucky
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a multi-arm, phase II trial for rapid efficacy and toxicity assessment of multiple therapies immediately after COVID19 positive testing in high-risk individuals. Therapies include stand-alone or combination treatment with hydroxychloroquine, azithromycin, ivermectin, or camostat mesilate, artemesia annua. The hypothesis of this study is that the addition of agents that inhibit viral entry or replication of SARS-CoV-2 virus replication in will be devoid of additional moderate to severe toxicities, will prevent clinical deterioration, and will improve viral clearance in high risk individuals.


Description:

Coronavirus Disease 2019 (COVID-19) is a highly contagious disease, caused by a novel enveloped RNA beta-coronavirus, also known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The first case of this unprecedented outbreak "pneumonia of unknown etiology" was reported in Wuhan City, Hubei Province, China on December 8th, 2019 and reported to the World Health Organization (WHO) on December 31st, 2019. WHO declared a COVID-19 global emergency on January 30, 2020, and then categorized the outbreak as a pandemic on March 11, 2020. As of April 22, 2020, more than 2,628,894 confirmed cases of COVID-19 worldwide and 182,740 people globally have died from COVID-19 since it emerged in China, according to the data from Johns Hopkins University. While the majority of patients with COVID-19 develop mild or uncomplicated illness, approximately 20-30% of hospitalized patients have required intensive care support and 5% of those have multi-organ failure or shock. The case fatality rate ranges from 1 to 4% and it is higher among those with pre-existing comorbid conditions such as cardiovascular disease, diabetes mellitus, obesity, chronic respiratory disease, hypertension and cancer. The vast majority of patients present with fever (83-99%), cough (59-82%), fatigue (44-70%), anorexia (40-84%), shortness of breath (31-40%), sputum production (28-33%), myalgias (11-35%). Less than 10% of patients will present with headache, confusion, rhinorrhea, sore throat, hemoptysis, vomiting, or diarrhea. Anosmia or ageusia proceeding the onset of respiratory symptoms has been anecdotally reported. To date, treatments for COVID-19 in high risks individuals remain experimental and therapeutic strategies to deal with the infection are at best supportive, with prevention aimed at reducing transmission in the community as the best weapon. No proven therapies have been demonstrated to prevent the progression of COVID-19 to severe illness and this is a critical unmet need for high-risk individuals and warrants study. Recently, the Infectious Disease Society of America has made recommendations for the treatment of patients with COVID-19, focusing on inpatient care, and recommending randomized trials where possible as the best step to improve treatment outcomes and to increase our understanding of this coronavirus pandemic. Discoveries in this area may inform clinicians on effective treatment for low-risk individuals who progress to severe illness, as well.


Recruitment information / eligibility

Status Terminated
Enrollment 13
Est. completion date January 12, 2022
Est. primary completion date December 21, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria - Age =18 years - Laboratory-confirmed SARS-CoV-2 infection within the past 7 days or the presence of symptoms or physical examination signs providing high probability of COVID-19 disease - Patients must have adequate organ and marrow function measured within the last 6 months - Subjects must have at least one of the following high-risk features for clinical deterioration: - Hypertension - Diabetes Mellitus - Moderate to severe Chronic Obstructive Pulmonary Disease, Emphysema, Cystic Fibrosis, or Asthma - Cancer patients who have received any immunosuppressive drugs within a year from enrollment - Sickle Cell disease or thalessemia - Age > or = 50 - BMI > or = 30 - Living in a nursing home or long-term facility - Underlying serious heart condition as determined by the treating physician - Immunocompromised subject as defined by the treating physician or COVID-19 Telehealth Treatment Team Exclusion Criteria - Severe or life threating COVID - Weight less than 45 kg. - Pregnant or breast-feeding females - Subjects on dialysis or with creatinine clearance < 45 ml/min - Existing DMID Toxicity Scale for Determining Severity of Adverse Events grade 3 or greater hepatic failure - Previously documented moderate or severe retinopathy or macular degeneration - Uncontrolled Seizure disorder - Prolonged QT, defined as QTc =470 milliseconds for men and as QTc =480 for women using Bazett's formula - Known allergy to artesunate, artemisia annua, hydroxychloroquine, macrolides, 4-aminoquinolines, camostat mesilate, or other agents to be used in the trial. - Currently receiving any study medications for other indications - Concurrent use of medication that would cause drug-drug interactions - Patients with psychiatric illness/social situations that would limit compliance

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ivermectin
Ivermectin: Days 1-2: Weight < 75kg: 4 tabs (12 mg total daily dose) Days 1-2: Weight > 75kg: 5 tabs (15 mg total daily dose)
Camostat Mesilate
Days 1-14: 2 tab TID after a meal (600 mg total daily dose)
Dietary Supplement:
Artemesia annua
Days 1-14: tea or coffee pod TID (1350 mg total daily dose)
Drug:
Artesunate
Days 1-14:

Locations

Country Name City State
United States University of Kentucky Markey Cancer Center Lexington Kentucky

Sponsors (1)

Lead Sponsor Collaborator
Susanne Arnold

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical Deterioration Number of patients experiencing clinical deterioration. Clinical deterioration is defined as a less than a 2-point change from the initial COVID 7-Point Ordinal Outcomes Scale within 14 days from the study start. This scale ranges from 1-7. Lower scores indicate worse outcomes (death); higher scores indicate fewer symptoms and better outcomes. 14 days
Secondary Change in Viral Load The change in (clearance of) viral RNA will be measured by PCR testing at days 1, 14, 28, and 40 days. 40 days
Secondary Rate of Organ Failure Number of patients that experienced severe respiratory or other organ failure. 28 days
Secondary Progression to ICU Care or Ventilation Percentage of patients requiring ICU admission or ventilation. 28 days
Secondary Number of Participants Who Had a Change in Clinical Status Measured by Decrease in COVID 7-point Ordinal Scale Number of participants who died or had greater than a 2-point decrease in COVID 7-Point Ordinal Outcomes Scale from Day to Day 14.
COVID 7-point ordinal outcomes scale:
Death
Hospitalized on invasive mechanical ventilation or ECMO
Hospitalized on non-invasive ventilation or high flow nasal cannula
Hospitalized on supplemental oxygen
Hospitalized not on supplemental oxygen
Not hospitalized with limitation in activity (continued symptoms)
Not hospitalized without limitation in activity (no symptoms)
14 days
Secondary Mortality Percentage of patients who have died by day 14. 14 days
Secondary Rate of Severe Adverse Events Percentage of patients experiencing severe adverse events, defined as grade 3 non-hematologic or greater by DMID Toxicity Scale for Determining Severity of Adverse Events. 14 days
Secondary Number of Patients That Required Oxygen Supplementation Number of patients that required oxygen supplementation during study treatment Days 1-28 28 days
Secondary Number of Patients That Required Mechanical Ventilation Number of patients that required mechanical ventilation during the study period. Days 1-28 28 days
Secondary Number of Patients Who Required Vasopressors Number of patients who required vasopressor treatment Days 1 to 28 28 days
Secondary Number of Patients Who Required ICU Services Number of patients who required ICU services during study treatment Days 1-28. 28 days
Secondary Number of Patients That Required Hospitalization Number of patients that required hospitalization during study treatment 28 days
Secondary Heart Function Proportion of patients with significant changes in ECG findings, including heart rate, ECG intervals (PR, QTcB, QTcF), conduction changes, or abnormalities including severe QTc prolongation of > 500 ms. 28 days
See also
  Status Clinical Trial Phase
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Recruiting NCT04410510 - P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19 Phase 2/Phase 3
Active, not recruiting NCT04420676 - Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection N/A
Completed NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease Phase 2
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Completed NCT04425317 - Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients N/A
Completed NCT04526769 - Detecting SARS-CoV-2 in Tears
Withdrawn NCT04456426 - Characteristics of Patients With COVID-19 in Meta State, Colombia
Completed NCT04425720 - Use of Remote Monitoring for COVID-19 Patient N/A
Suspended NCT04385771 - Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation N/A
Completed NCT04419610 - RAS and Coagulopathy in COVID19 Early Phase 1
Completed NCT04546581 - Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC) Phase 3
Completed NCT04435327 - Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
Terminated NCT04530448 - Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization Phase 4
Not yet recruiting NCT04524156 - COVID-19 : Transcutaneous pO2 and pCO2 as Predictive Factors for Acute Respiratory Destress Syndrome in Patients Affected With SARS-Cov-2 N/A
Completed NCT04441710 - Caregiver Serological Monitoring Extended Secondarily to Patients With the SARS-CoV-2 Coronavirus
Completed NCT04357834 - WAVE. Wearable-based COVID-19 Markers for Prediction of Clinical Trajectories
Not yet recruiting NCT04392427 - New Antiviral Drugs for Treatment of COVID-19 Phase 3
Terminated NCT04614025 - Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19 Phase 2
Completed NCT04402957 - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19) Phase 2